Impending Flop for Brand Antiretrovirals in the Emerging Markets?
Dionisio Daniele 1 , &, Messeri Daniela 2
Identifiers and Pagination:Year: 2008
First Page: 68
Last Page: 71
Publisher ID: TOAIDJ-2-68
Article History:Received Date: 19/6/2008
Revision Received Date: 9/7/2008
Acceptance Date: 11/7/2008
Electronic publication date: 16/8/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Forecasts from Country choices, South-South partnerships and Clinton Foundation-UNITAID coalition show that present policies for brand ARVs are at the risk of flop in emerging South markets such as India, China, Thailand and Brazil.
The dynamics explored in this article highlight the risks the originator companies are running in the emerging markets, along with their interest in direct agreements with the generic industry for the manufacturing and marketing of ARVs.
Resulting information here would suggest the brand enterprises:
- To look for fast registration of their ARVs by regulatory authorities in all countries enlisted for differential pricing.
- To secure all formulations differentiated prices.
- To align with the Clinton-UNITAID prices for the corresponding generics.
- To pursue flexible negotiations with the generic companies to secure both counterparts long-term advantages.